StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Revenue Recognized from Prior-Period Completed Tests by Year

Revenue Recognized from Prior-Period Completed Tests — Cash Collection True-Ups ($M) ($M)

Natera Revenue Recognized from Prior-Period Completed Tests: $194M in FY2025, up 28.6% from a year earlier.

Latest, FY2025
194
Period ended Dec 31, 2025
Change on a year earlier
+28.6%
151 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (2026-02-27) ↗

Revenue recognized in the current period from cash collections and appeal recoveries exceeding prior variable consideration estimates for tests completed in prior periods ($52.3M or $0.36/sh in Q2 2026; $161.3M or $1.18/sh in FY2025).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRevenue Recognized from Prior-Period Completed Tests — Cash Collection True-Ups ($M) ($M)Year on yearSource
FY2025Dec 31, 2025194+28.6%Form 10-K (2026-02-27) ↗
FY2024Dec 31, 2024151+2,752.8%Form 10-K (2026-02-27) ↗
FY2023Dec 31, 20235.30-72.8%Form 10-K (2026-02-27) ↗
FY2022Dec 31, 202219.5+56.0%Form 10-K (2025-02-28) ↗
FY2021Dec 31, 202112.5–Form 10-K (2024-02-29) ↗

Breakdown

What makes up revenue Recognized from Prior-Period Completed Tests

Cite this data

StockData. (2026). Natera Revenue Recognized from Prior-Period Completed Tests ($M), annual FY2021–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rev-prior-period-trueup

See every metric in the Natera KPI table. Data updated Nov 2, 2026.